...
机译:2型糖尿病患者切除非小细胞肺癌的预后因素
Department of MedicineThe Graduate School of Yonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
Department of Thoracic and Cardiovascular SurgeryYonsei UniversitySeoul Republic of Korea;
carcinoma; diabetes mellitus; type 2; hydroxymethylglutaryl‐CoA reductase inhibitors; non‐small cell lung; prognosis;
机译:2型糖尿病患者切除非小细胞肺癌的预后因素
机译:P1.16-37可操作的非小细胞肺癌患者糖尿病患者的临床病理特征及预后因素
机译:糖尿病糖尿病是小细胞肺癌患者存活的预后因素吗?
机译:手术切除的Ⅰ期非小细胞肺癌患者FDG摄取是复发的生物学预后因素
机译:二甲双胍的使用与2型糖尿病患者大肠癌和肺癌的发生率
机译:ABO血型在中国根治性非小细胞肺癌患者中的预后作用:单个癌症中心1601例病例的回顾性分析
机译:P3.16-019 2型糖尿病患者切除非小细胞肺癌的预后因素